This care card's answer
The list of allowed ingredients changes through a final rule.
The Food and Drug Administration (FDA), the U.S. medicine regulator, keeps the 503A Bulks List. It lists extra raw ingredients an ordinary pharmacy may use to make medicines to order. The other compounding rules still apply.
FDA must publish a proposed rule, take public comments and issue a final rule to add an ingredient to that list.
No official record of the July peptide meeting's votes had been published by FDA as of September 26, 2026.
Separate a proposal from a decision.
Ask whether the report describes an agenda, a staff recommendation, a committee vote or a final rule. They are different steps. A headline may leave the step unclear.
Taking back a request does not give permission.
People or groups had asked FDA to allow certain peptide ingredients in made-to-order medicines. They later took back those requests. Those ingredients appear in a separate FDA table; the page gives April 22, 2026, as the date it was current.
A pharmacy gains no permission to use the ingredient when a request is taken back. FDA still lists its safety concerns beside those ingredients.
FDA's concerns for some of these injected peptides include unwanted material in the medicine and the body's reaction to it. For some, FDA has too little information to know whether they could harm people.
Ask for the rule that applies to the exact ingredient and form being proposed.
Take this to the conversation
Is there a final rule for this substance and form, or only a report about advice?
Ask for the answer in plain words. Keep it with your visit notes.
Notes behind this answer
- FDA: the July committee meeting record
As of September 26, 2026, FDA's published meeting records did not tell us how the committee voted. Ask for the final rule that applies to your medicine.
- FDA: the meeting's introductory briefing
Read why the committee gives advice and FDA still has to make a final decision.
- FDA: ingredient requests taken back
This table names ingredients whose requests were taken back, with FDA's safety concerns still beside them.